Continuous Manufacturing Market Size & Share 2025 - 2034

Continuous Manufacturing Market Size

The global continuous manufacturing market was valued at USD 4.5 billion in 2024. The market is expected to grow from USD 5.1 billion in 2025 to USD 16.2 billion in 2034, at a CAGR of 13.7% during the forecast period, according to the latest report published by Global Market Insights Inc.

The continuous manufacturing market is witnessing robust growth, driven by increasing demand for efficient, high-quality, and scalable pharmaceutical production. With regulatory bodies actively supporting the shift from batch to continuous processes, manufacturers are embracing integrated systems that offer superior control, reduced waste, and faster turnaround times. As industry moves toward more personalized and small-batch therapies, continuous manufacturing is emerging as a key enabler of flexible, patient-centric production. The growing emphasis on real-time quality monitoring and operational efficiency is further accelerating adoption across both small molecule and biologics segments.
 

This market segment is transforming pharmaceutical production by enabling faster, more efficient, and highly controlled manufacturing workflows. Leading companies such as GEA Group Aktiengesellschaft, Thermo Fisher Scientific, Siemens Healthineers, Continuus Pharmaceuticals, and L.B. Bohle Maschinen und Verfahren are at the forefront of this transformation. These players maintain their competitive edge through innovations in integrated systems, real-time monitoring technologies, and AI-powered software platforms. Their strategic focus on improving product quality, reducing operational costs, and supporting regulatory compliance is accelerating the adoption of continuous manufacturing across both small molecule and biologics production environments.
 

The continuous manufacturing market is witnessing sharp growth, expanding from USD 3.3 billion in 2021 to USD 4 billion in 2023. This growth is closely tied to the increasing push for modernization in pharmaceutical production. Regulatory bodies are actively supporting the adoption of continuous manufacturing due to its potential to enhance product quality, reduce waste, and improve supply chain resilience. The shift is further fueled by the rising demand for personalized therapies and small-batch production, which require flexible and efficient manufacturing systems. As pharmaceutical companies seek to streamline operations and meet evolving patient needs, continuous manufacturing is emerging as a transformative solution across both small molecule and biologics segments.  
 

Moreover, the pursuit of operational efficiency and cost reduction is a major driver of growth in the continuous manufacturing market. Traditional batch manufacturing often involves lengthy production cycles, significant material waste, and complex quality control procedures. In contrast, continuous manufacturing streamlines production by integrating unit operations into a seamless flow, reducing downtime and improving resource utilization. This shift enables pharmaceutical companies to lower production costs, accelerate time-to-market, and respond more flexibly to demand fluctuations. As the industry faces increasing pressure to optimize margins and scale personalized therapies, continuous manufacturing is becoming a strategic imperative for both innovators and generic drug producers.
 

Continuous manufacturing systems are advanced pharmaceutical production technologies designed to streamline the end-to-end manufacturing of solid dosage forms such as tablets and capsules. These systems integrate multiple unit operations such as blending, granulation, drying, and compression into a seamless, uninterrupted process. By leveraging automation, real-time monitoring, and process analytical technologies (PAT), continuous manufacturing enhances precision, consistency, and efficiency in drug production. This approach significantly reduces manual intervention, production time, and waste, making it a transformative solution for modern pharmaceutical workflows.
 

Continuous Manufacturing Market Trends

• The global pharmaceutical manufacturing landscape is undergoing a significant transformation, with continuous manufacturing (CM) emerging as a key enabler of efficiency, quality, and agility. This shift is driven by the growing demand for faster drug development, rising complexity of therapies, and the need for resilient supply chains. Regulatory bodies such as the FDA and EMA are actively supporting CM adoption through guidance frameworks and expedited approval pathways.
   
• In response, pharmaceutical companies are increasingly transitioning from traditional batch processes to continuous, end-to-end production models. CM systems offer substantial advantages, including reduced production time, real-time quality monitoring, and lower operational costs. These benefits are particularly valuable in the production of personalized medicines, small-batch therapies, and biologics, where flexibility and precision are critical.
   
• Technological innovation is a major catalyst in this market. Leading players are integrating process analytical technologies (PAT), AI-driven control systems, and modular equipment to enable seamless, data-rich manufacturing environments. For example, GEA’s ConsiGma platform exemplifies how automation and predictive analytics are reshaping pharmaceutical production.
   
• The demand for agile, scalable, and compliant manufacturing solutions is rising, especially among contract development and manufacturing organization (CDMOs) and biotech firms aiming to accelerate time-to-market. Continuous manufacturing enables on-demand production, minimizes human error, and enhances product consistency making it a strategic imperative for the future of pharmaceutical innovation.
   

Continuous Manufacturing Market Analysis

Based on product type, the market is divided into integrated systems, semi-continuous systems and software. The integrated systems segment accounted for 44.2% of the market share in 2024 primarily due to their ability to offer end-to-end automation, real-time quality control, and seamless scalability. The segment is expected to exceed USD 7.1 billion by 2034, growing with a CAGR of 13.7% through 2034. On the other hand, software segment is expected to grow with 14.2% CAGR through 2034. The growth of this segment is primarily driven by the increasing integration of advanced analytics, AI-based process control, and real-time monitoring tools into continuous manufacturing workflows.
 

• The integrated systems segment is the leading component of the global continuous manufacturing market. This dominance is attributed to their ability to deliver end-to-end, fully automated production workflows, combining material feeding, blending, granulation, drying, tableting, and coating into a single, seamless process. These systems are especially favored by large pharmaceutical manufacturers aiming to reduce production time, enhance product consistency, and ensure regulatory compliance.
   
• Integrated systems segment is valued for their high throughput, real-time quality control, and minimal manual intervention. They enable continuous, uninterrupted production, which significantly reduces downtime and batch variability. As the demand for agile and scalable manufacturing grows particularly for personalized medicines and small-batch biologics these systems are becoming central to next-generation pharmaceutical operations.
   
• Companies are enhancing system capabilities with AI-powered process control, digital twins, and advanced PAT (Process Analytical Technology) tools. For instance, Continuus Pharmaceuticals offers fully integrated continuous manufacturing platforms that combine drug substance and drug product operations, enabling rapid, flexible, and cost-effective production. Their Integrated Continuous Manufacturing (ICM) approach exemplifies how modular, closed-loop systems can revolutionize pharmaceutical supply chains.
   
• The segment’s expansion is also supported by increasing regulatory support and industry-wide digital transformation. As pharma companies seek to modernize legacy infrastructure and meet evolving quality standards, integrated systems offer a future-ready solution that aligns with both efficiency goals and compliance requirements.
   

Based on applications, continuous manufacturing market is classified into finished product manufacturing and API manufacturing. The finished product manufacturing segment dominated the market in 2024 and is expected to reach USD 10.6 billion by 2034.
 

• The finished product manufacturing segment is the leading application area in the global continuous manufacturing market, dominating in 2024. This growth is driven by the increasing adoption of continuous processes for producing oral solid dosage forms, injectables, and other final pharmaceutical products with greater speed, consistency, and cost-efficiency.
   
• Continuous manufacturing systems are transforming how finished pharmaceutical products are made by enabling real-time quality control, reduced production cycles, and minimal manual intervention. These systems streamline the entire production line from blending and granulation to tableting and coating ensuring uniformity and reducing the risk of batch failures.
   
• The demand for faster time-to-market, especially for personalized medicines and small-batch therapies, is pushing manufacturers to adopt integrated continuous platforms. These platforms support on-demand production, reduce inventory costs, and enhance supply chain agility key advantages in today’s dynamic pharmaceutical landscape.
   
• The segment is also benefiting from regulatory encouragement and global health priorities that emphasize quality, efficiency, and accessibility. As pharmaceutical companies modernize their manufacturing infrastructure, finished product continuous manufacturing is poised to become the new standard for high-quality, patient-centric drug production.
   

Based on therapeutic type, continuous manufacturing market is classified into small molecules and large molecules. The small molecules segment dominated the market in 2024 and is expected to reach USD 10.4 billion by 2034.
 

• The small molecules segment is the dominant therapeutic category in the global continuous manufacturing market, accounting for the largest revenue share in 2024. This leadership is driven by the widespread use of small molecule drugs in chronic disease management, infectious diseases, and oncology, as well as their compatibility with continuous manufacturing platforms.
   
• Small molecule drugs are well-suited for continuous production due to their relatively simple chemical structures, established formulation pathways, and high-volume demand. Continuous systems enable efficient synthesis, formulation, and packaging of these drugs, significantly reducing production time and improving batch-to-batch consistency.
   
• The segment benefits from technological advancements in process control, real-time analytics, and modular equipment design. These innovations allow manufacturers to optimize reaction conditions, monitor critical quality attributes, and scale production rapidly. Companies are pioneering integrated platforms that streamline the entire lifecycle of small molecule drug production from API synthesis to finished dosage forms.
   
• With the growing demand for cost-effective, high-quality therapies, especially in emerging markets, the small molecules segment is expected to remain the backbone of continuous manufacturing adoption. Its scalability, flexibility, and proven success across therapeutic areas make it a cornerstone of future pharmaceutical innovation.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on end use, continuous manufacturing market is classified into R&D departments and full-scale manufacturing companies. The full-scale manufacturing companies segment dominated the market in 2024 and is expected to reach USD 10.7 billion by 2034. The full-scale manufacturing companies’ segment is further segmented into contract manufacturing organizations (CMOs) and pharmaceutical and biotechnological companies.
 

• The full-scale manufacturing companies’ segment is the dominant end use category in the global continuous manufacturing market, leading in 2024. This dominance is driven by the growing need for high-volume, cost-efficient, and quality-assured drug production across global pharmaceutical supply chains.
   
• Large pharmaceutical manufacturers are increasingly adopting continuous manufacturing systems to streamline operations, reduce production costs, and enhance product consistency. These systems enable uninterrupted workflows, real-time quality monitoring, and faster batch release, making them ideal for scaling up commercial drug production.
   
• The shift toward digital transformation and regulatory compliance is pushing full-scale manufacturers to invest in integrated platforms that combine automation, AI-driven process control, and advanced analytics. These technologies support predictive maintenance, reduce human error, and ensure adherence to stringent quality standards.
   
• The increasing demand for global drug accessibility, coupled with the need for resilient and scalable manufacturing models, is expected to further strengthen this segment. As pharmaceutical companies expand their production capabilities to meet evolving healthcare needs, full-scale continuous manufacturing will remain a cornerstone of future-ready operations.
   

North America Continuous Manufacturing Market

• North America remains the leading region in the global continuous manufacturing industry, driven by strong regulatory support, advanced manufacturing infrastructure, and high adoption among large pharmaceutical companies. The region’s emphasis on quality, efficiency, and innovation continues to fuel demand for integrated and automated production systems across both small and large molecule drug manufacturing.
   
• The U.S. FDA has played a pivotal role in promoting continuous manufacturing through clear regulatory guidance, pilot programs, and expedited review pathways. This has encouraged early adoption among full-scale manufacturers and CDMOs seeking to modernize legacy batch systems and improve supply chain resilience.
   
• Pharmaceutical companies in North America are increasingly investing in modular, AI-powered platforms that support real-time monitoring, predictive analytics, and flexible production. These technologies are being deployed to accelerate time-to-market, reduce operational costs, and ensure consistent product quality especially in high-demand therapeutic areas such as oncology, cardiology, and rare diseases.
   
• The region also benefits from a robust ecosystem of technology providers, academic institutions, and government-backed research initiatives that support innovation in continuous manufacturing. Collaborations between pharma companies and engineering firms such as GEA Group, Thermo Fisher Scientific, and Continuus Pharmaceuticals are driving the development of next-generation systems tailored to North American market needs.
   

The U.S. continuous manufacturing market was valued at USD 1.3 billion and USD 1.4 billion in 2021 and 2022, respectively. The market size reached USD 1.8 billion in 2024, growing from USD 1.6 billion in 2023.
 

• The U.S. market is shaped by evolving regulatory frameworks, rising demand for agile production models, and increased investment in advanced manufacturing technologies. According to industry estimates, the U.S. accounts for a significant share of global pharmaceutical manufacturing, with continuous manufacturing gaining traction as a strategic solution for improving efficiency, quality, and supply chain resilience.
   
• The growing adoption of continuous manufacturing aligns with broader trends in digital health transformation, precision medicine, and patient-centric drug development. These systems enable faster production cycles, real-time quality control, and reduced operational costs, making them attractive to large pharmaceutical companies.
   
• While overall U.S. healthcare spending continues to rise, the pharmaceutical sector is under pressure to deliver cost-effective and scalable solutions. Continuous manufacturing offers a pathway to meet these demands, especially in the production of small molecules and personalized therapies.
   
• The U.S. market also benefits from a strong innovation ecosystem, with public-private partnerships, and academic research driving advancements in AI-powered process control, modular equipment design, and real-time analytics. As demand grows for biologics, rare disease treatments, and small-batch production, continuous manufacturing is poised to become a cornerstone of U.S. pharmaceutical strategy.
   

Europe Continuous Manufacturing Market

The European market accounted for USD 1.2 billion in 2024 and is anticipated to show lucrative growth over the forecast period.
 

• Europe plays a pivotal role in the global continuous manufacturing market, supported by its advanced healthcare infrastructure, strong regulatory frameworks, and growing emphasis on sustainable production.
   
• Also, the region is undergoing a significant demographic shift, with the proportion of people aged 65 and older projected to rise from 21% in 2023 to 29% by 2050. This aging trend is driving demand for efficient, high-quality drug production particularly for chronic conditions and personalized therapies where continuous manufacturing offers clear advantages in scalability, precision, and speed.
   
• Europe benefits from a well-defined regulatory environment, with the European Medicines Agency (EMA) adopting the ICH Q13 guideline which outlines scientific and regulatory considerations for the development, implementation, operation, and lifecycle management of continuous manufacturing (CM). Building on existing ICH Quality guidelines, ICH Q13 provides clarity on CM concepts and supports both new product development (including new drugs, generics, and biosimilars) and the conversion of batch processes to CM for existing products.
   
• The guideline applies to drug substances and drug products for chemical entities and therapeutic proteins, and its principles may extend to other biological and biotechnological entities. This harmonized framework is accelerating CM adoption across Europe, particularly among full-scale manufacturers and CDMOs, by reducing regulatory uncertainty and encouraging innovation in pharmaceutical production.
   

Germany dominates the European continuous manufacturing market, showcasing strong growth potential.
 

• Germany represents a key segment of the European continuous manufacturing market, supported by its advanced industrial infrastructure, strong public and private investment in pharmaceutical innovation, and leadership in precision-driven production technologies. As Europe’s largest pharmaceutical market and exporter, Germany plays a central role in shaping the region’s transition from batch to continuous manufacturing.
   
• The country’s aging population and rising prevalence of chronic diseases are driving demand for efficient, high-quality drug production. According to Eurostat, On 1 January 2024, the EU population was estimated at 449.3 million people and more than one-fifth (21.6%) of it was aged 65 years and over, a demographic trend that is increasing the need for scalable and reliable drug manufacturing solutions.
   
• Germany’s leadership in engineering, automation, and digital integration positions it as a fertile ground for continuous manufacturing adoption. Pharmaceutical companies and CDMOs across the country are increasingly deploying modular AI-powered systems to streamline production, reduce costs, and ensure regulatory compliance. The adoption of the ICH Q13 guideline by the EMA further supports this transition by providing a harmonized framework for CM implementation.
   
• Also, the country is home to several leading equipment manufacturers and solution providers that are driving innovation in continuous manufacturing. As demand grows for biologics, personalized therapies, and small-batch manufacturing, Germany is poised to lead Europe’s shift toward continuous pharmaceutical production.
   

Asia Pacific Continuous Manufacturing Market

The Asia Pacific market is anticipated to grow at the highest CAGR during the analysis timeframe.
 

• The Asia-Pacific region is emerging as a critical growth market for continuous manufacturing, driven by its large and aging population, rising burden of chronic diseases, and increasing investment in healthcare infrastructure and manufacturing modernization. Countries such as India, China, Japan, and South Korea are actively expanding their pharmaceutical production capabilities, making the region a strategic hub for continuous manufacturing adoption.
   
• The region is also witnessing a strong push toward digital health transformation, with governments and private players investing in automation, AI integration, and smart manufacturing platforms. Companies such as STEER World and Syntegon Technology GmbH are contributing to this shift by offering continuous granulation and blending systems tailored to regional needs.
   
• With growing support from regulatory bodies, increasing CDMO activity, and a focus on biologics and personalized medicine, the Asia-Pacific region is poised to become a major driver of global growth in the continuous manufacturing market. As infrastructure and expertise continue to evolve, CM technologies are expected to play a central role in shaping the future of drug production across the region.
   

China continuous manufacturing market is estimated to grow with a significant CAGR, in the Asia Pacific continuous manufacturing market.
 

• China is a cornerstone of the global continuous manufacturing market, owing to its vast population, rapidly expanding pharmaceutical sector, and strong government support for manufacturing modernization. As one of the world’s largest producers and consumers of medicines, China is actively investing in advanced technologies to improve drug quality, reduce production costs, and enhance supply chain resilience.
   
• The country’s aging population and rising prevalence of chronic diseases are driving demand for scalable and efficient drug manufacturing solutions. China’s healthcare reforms and digital health initiatives are accelerating the adoption of automated, AI-integrated manufacturing platforms across both public and private pharmaceutical enterprises.
   
• These systems are increasingly used for the production of small molecules, generics, and high-demand therapies, aligning with the country’s push toward precision medicine and regulatory compliance.
   
• As China continues to prioritize pharmaceutical innovation, quality assurance, and global competitiveness, continuous manufacturing technologies are poised to play a central role in shaping the future of drug production across the country.
   

Latin American Continuous Manufacturing Market

Brazil leads the Latin American continuous manufacturing market and is expected to exhibit remarkable growth during the analysis period.
 

• Brazil is a leading market for continuous manufacturing in Latin America, driven by its large population, growing pharmaceutical sector, and increasing focus on modernizing drug production infrastructure. As the largest pharmaceutical market in South America, Brazil is actively investing in advanced manufacturing technologies to improve drug quality, reduce production costs, and expand access to essential medicines.
   
• The country faces a substantial burden of chronic diseases such as diabetes, hypertension, and cancer, which require consistent and scalable drug production. Which enhances the demand for efficient, high-throughput manufacturing systems making continuous manufacturing a strategic solution for both domestic supply and export growth.
   
• Brazil’s National Health Surveillance Agency (ANVISA) has been aligning with international regulatory standards, including ICH guidelines, to support innovation and ensure quality in pharmaceutical manufacturing. These efforts are encouraging the adoption of automated, AI-integrated continuous systems across both public and private sector manufacturers.
   
• As Brazil continues to expand its pharmaceutical exports and strengthen its domestic production capabilities, continuous manufacturing technologies are expected to play a central role in improving supply chain resilience, reducing batch failures, and enhancing regulatory compliance. With growing support from government and industry stakeholders, Brazil is poised to become a key driver of continuous manufacturing adoption in Latin America.
   

Middle East and Africa Continuous Manufacturing Market

The Saudi Arabia market for continuous manufacturing is expected to experience substantial growth in the Middle East and Africa continuous manufacturing market in 2024.
 

• Saudi Arabia is a key market for continuous manufacturing in the Middle East, driven by its expanding healthcare infrastructure, strategic investments in pharmaceutical production, and national focus on digital transformation under Vision 2030. The country is actively working to localize drug manufacturing and reduce dependency on imports, creating strong demand for scalable, efficient, and quality-driven production technologies.
   
• Saudi Arabia faces a rising burden of chronic diseases, including diabetes, cardiovascular conditions, and cancer. With a diabetes prevalence of 23.1% in 2024, the need for consistent, high-quality drug production is growing making continuous manufacturing a vital solution for meeting therapeutic demand while ensuring product safety and efficacy.
   
• Under Vision 2030, the government is modernizing its pharmaceutical sector through public-private partnerships, regulatory reforms, and investment in smart manufacturing platforms. Continuous manufacturing systems featuring real-time analytics, AI-powered process control, and modular scalability are being adopted by both public health institutions and private manufacturers to improve production speed, reduce waste, and enhance compliance.
   
• As Saudi Arabia continues to prioritize precision medicine, supply chain resilience, and healthcare innovation, continuous manufacturing is poised to play a central role in shaping the future of pharmaceutical production across the Kingdom.
   

Continuous Manufacturing Market Share

The continuous manufacturing industry is characterized by a mix of established global leaders and specialized technology providers, resulting in a dynamic and innovation-driven competitive landscape. The top five companies GEA Group Aktiengesellschaft, Thermo Fisher Scientific, Siemens Healthineers, Continuus Pharmaceuticals, and L.B. Bohle Maschinen und Verfahren collectively account for approximately 60% of the global market share. Their leadership is anchored in comprehensive product portfolios, global reach, and sustained investment in automation, AI integration, and modular system design.
 

To strengthen their market positions, these companies are pursuing multi-pronged strategies, including strategic collaborations with pharmaceutical manufacturers and CDMOs, expansion into emerging markets, and continuous enhancement of their platforms. Their focus on end-to-end integrated systems, real-time process monitoring, and regulatory-compliant solutions is helping pharma companies achieve faster production cycles, improved quality control, and greater operational efficiency.
 

Overall, the market is witnessing intensified competition and greater diversity, as both established and emerging players evolve their offerings to meet the global demand for efficient, high-quality, and digitally enabled pharmaceutical production.
 

Continuous Manufacturing Market Companies

Prominent players operating in the continuous manufacturing industry are as mentioned below:

• Continuus Pharmaceuticals
• Coperion GmbH 
• FREUND CORPORATION
• GEA Group Aktiengesellschaft
• Gebrüder Lödige Maschinenbau
• Gericke
• Glatt
• KORSCH
• L.B. Bohle Maschinen und Verfahren
• Munson Machinery
• Scott Equipment Company
• Siemens Healthineers
• STEER World
• Sturtevant Inc 
• Syntegon Technology
• Thermo Fisher Scientific
   
• Continuus Pharmaceuticals

Continuus Pharmaceuticals is a pioneering force in the continuous manufacturing market, known for its Integrated Continuous Manufacturing (ICM) platforms that combine drug substance and drug product operations. The company focuses on end-to-end solutions that enable rapid, flexible, and cost-effective production, particularly for small molecules and personalized therapies. Its commitment to innovation, regulatory alignment, and scalable design makes it a preferred partner for pharma companies seeking to modernize their manufacturing infrastructure.
 

• L.B. Bohle Maschinen und Verfahren

L.B. Bohle is a key contributor to the continuous manufacturing market, offering a wide range of modular systems for blending, granulation, drying, and tablet coating. The company is recognized for its precision engineering, process reliability, and ability to support both pilot-scale and full-scale production. Its continuous manufacturing solutions are widely adopted across Europe and Asia, helping pharmaceutical firms achieve consistent quality and streamlined operations.
 

• KORSCH

KORSCH plays a significant role in the continuous manufacturing space. The company provides engineering solutions that integrate seamlessly with upstream and downstream CM systems, enabling uninterrupted production and real-time quality control. KORSCH’s focus on flexibility, automation, and GMP compliance has positioned it as a trusted provider for pharmaceutical manufacturers transitioning to continuous workflows.
 

Continuous Manufacturing Industry News

• In July 2024, GEA Group Aktiengesellschaft announced a strategic collaboration with Hovione, combining GEA’s engineering expertise with Hovione’s pharmaceutical development and manufacturing capabilities. The partnership aims to advance continuous manufacturing technologies and promote broader market acceptance. As part of this initiative, GEA introduced the ConsiGma CDC Flex a versatile system capable of operating in both continuous and batch modes. These developments reflect GEA’s commitment to innovation and its role in shaping the future of pharmaceutical manufacturing.
   
• In October 2024, Thermo Fisher Scientific unveiled Accelerator Drug Development, a comprehensive 360° CDMO and CRO platform designed to streamline the molecule-to-medicine journey for pharmaceutical and biotech companies. Announced during CPHI Milan 2024, the platform integrates manufacturing, clinical research, and supply chain services, supporting a wide range of modalities including small molecules, biologics, and cell and gene therapies. These initiatives reflect Thermo Fisher’s growing momentum in continuous manufacturing and its role in addressing global health challenges with speed, quality, and efficiency.
   

The continuous manufacturing research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Billion from 2021 - 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• Integrated Systems
• Semi-continuous systems
  • Continuous granulators
  • Continuous coaters
  • Continuous blenders
  • Continuous dryers
  • Continuous compressors
  • Other semi-continuous systems

• Software

Market, By Application

• Finished product manufacturing
  • Solid dosage
  • Semi solid dosage
  • Liquid dosage
• API manufacturing

Market, By Therapeutic Type

• Small molecule
• Large molecules

Market, By End Use

• R&D departments
  • Research institutes
  • Contract research organizations (CROs)
• Full-scale manufacturing companies
  • Contract manufacturing organizations (CMOs)
  • Pharmaceutical and biotechnological companies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE